Compare Citius Pharmaceuticals Inc (CTXR) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Yum! Brands, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Yum! Brands, Inc. trades at $144.82 (market cap $39.02B). The key difference: Yum! Brands, Inc. is far larger — about 2864.9× Citius Pharmaceuticals Inc's market cap, and Yum! Brands, Inc. pays a 2.1% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Yum! Brands, Inc. for 132 Days on average.
| CTXR | YUM | |
|---|---|---|
Market Cap | $13.62M | $39.02B |
Volume | 132,438 | 2,597,636 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $168.16 |
52-Week Low | $0.48 | $135.77 |
Typical Hold Time | 17 Days | 132 Days |
Enterprise Value | $3.79M | $50.63B |
Dividend Yield | — | 2.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
YUM trades at $143.00, up 1.89% over 24 hours, with a bullish technical signal and strong support at $141. Revenue has grown from $6.8B in 2022 to $8.2B in 2025, with net income reaching $1.56B. Recent news highlights KFC's new Open House restaurant concept in Texas, testing expanded menus and customer experiences.
The outlook remains positive with a consensus price target of $170.44, though risks include high debt levels and competitive pressures. Earnings have beaten expectations in two of the last three quarters, with Q3 2026 results pending. Analyst sentiment is mixed with 39.22% buy ratings, 54.9% hold, and 5.88% sell.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
